Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial

作者：Zhiwei Chen, Fang Yang, Jiang Zhou, Longhua Sun, Lin Wu, Zhengxiang Han, Yun Fan, Yanqiu Zhao, Xingya Li, Haipeng Xu, Xiangjiao Meng, Ying Liu, Zhiye Zhang, Hui Luo, Xuelei Ma, Xuezhen Ma, Qin Shi, Zhongmin Zhang, Runxiang Yang, Pingli Wang, Pinhua Pan, Xiaohong Ai, Jie Li, Xingxiang Pu, Zhiwu Wang, Jian Fang, Ming He, Yong‐Ming He, Shuliang Guo, Juan Li, Hongbiao Wang, Junqiang Zhang, Qian Chu, Xuewen Liu, Shenpeng Ying, Hongcheng Wu, Hongmei Sun, Yinghua Ji, Ming Zhou, Chao Cao, Kejing Tang, Zhengguo Li, Dairong Li, Zhihong Zhang, Jie Li, Jianya Zhou, Hongzhong Yang, Yingying Du, Hui Yang, Jian Shi, Hualin Chen, Wenting Li, Dongmei Lu, Mingxiu Hu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Shun Lu · 发表于：The Lancet · 年份：2025 · DOI：10.1016/s0140-6736(25)01848-3 · 被引用次数：35 · 研究领域：Cancer Immunotherapy and Biomarkers、Lung Cancer Treatments and Mutations、Lung Cancer Diagnosis and Treatment